Remdesivir is a delayed translocation inhibitor of SARS CoV-2 replication in vitro
Keyword(s):
Remdesivir is a nucleoside analog approved by the FDA for treatment of COVID-19. Here, we present a 3.9-Å-resolution cryoEM reconstruction of a remdesivir-stalled RNA-dependent RNA polymerase complex, revealing full incorporation of three copies of remdesivir monophosphate (RMP) and a partially incorporated fourth RMP in the active site. The structure reveals that RMP blocks RNA translocation after incorporation of three bases following RMP, resulting in delayed chain termination, which can guide the rational design of improved antiviral drugs.
2007 ◽
Vol 17
(18)
◽
pp. 5199-5203
◽
1982 ◽
Vol 257
(8)
◽
pp. 4610-4617
2008 ◽
Vol 89
(12)
◽
pp. 2923-2932
◽